Press release
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":" PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:\n\nJefferies Virtual Healthcare Conference – June 1-4, 2021\n\nJune 3, 2021, 2:30 p.m. ET – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation\n\nGoldman Sachs 42nd Annual Global Healthcare Conference – June 8-11, 2021\n\nJune 10, 2021, 2:10 p.m. ET – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation\n\n2021 Virtual Alpha-1 National Conference – June 10-12, 2021\n\nJune 12, 2021 – Javier San Martin, M.D., Arrowhead’s chief medical officer, will deliver an oral presentation\n\nVirtual Dana-Farber Harvard Cancer Center Symposium on HIF, VHL, and Kidney Cancer – June 17, 2021\n\nJune 17, 2021 – So Wong, Ph.D., Arrowhead’s senior director of biology, will deliver an oral presentation on the preclinical development of ARO-HIF2\n\nLifeSci Partners Genetic Medicines Summit 2021 – June 22, 2021\n\nJune 22, 2021 – Members of Arrowhead management will participate in a fireside chat presentation\n\nThe International Liver Congress™ 2021 - The Annual Meeting of the European Association for the Study of the Liver (EASL) – June 23-26, 2021\n\nTitle: ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH\nAuthors: Edward Gane, et al.\nType: Late-Breaking Poster\nDate and Time: June 23, 2021 at 8:00 CEST\n\nTitle: Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors\nAuthors: Edward Gane, et al.\nType: Oral Presentation\nDate and Time: June 25, 2021 at 15:15 CEST\n\nTitle: ARO-AAT an investigational RNAi therapeutic demonstrates improvement in liver fibrosis with reduction in intra-hepatic Z-AAT burden\nAuthors: Pavel Strnad, et al.\nType: Late-Breaking Oral Presentation\nDate and Time: June 26, 2021 at 12:15 CEST\n\n28th Annual FSHD Society International Research Congress – June 24-25, 2021\n\nJune 25, 2021 – Jonathan Van Dyke, Ph.D., Arrowhead’s senior scientist II of biology, will deliver an oral presentation on the preclinical development of ARO-DUX4\n\nA copy of the presentation materials a...